AIA
RPRX

Allegis Investment Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History

Allegis Investment Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-394,206
Closed -$260K – 254
2017
Q4 		$260K Buy
394,206
+165
+0% +$83 0.08% 189
2017
Q3 		$126K Sell
394,041
-4,751
-1% -$1.67K 0.03% 248
2017
Q2 		$183K Buy
398,792
+32,602
+9% +$23.7K 0.05% 256
2017
Q1 		$439K Buy
366,190
+21,703
+6% +$27.1K 0.12% 160
2016
Q4 		$455K Buy
344,487
+3,678
+1% +$6.4K 0.14% 151
2016
Q3 		$712K Sell
340,809
-1,900
-0.6% -$3.76K 0.28% 111
2016
Q2 		$569K Buy
342,709
+1,040
+0.3% +$2K 0.29% 107
2016
Q1 		$331K Sell
341,669
-2,607
-0.8% -$2.54K 0.19% 143
2015
Q4 		$417K Buy
+344,276
New +$1.11M 0.23% 114

Allegis Investment Advisors's RPRX Position: Q1 2018 in Review

Allegis Investment Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 394,206 shares — an estimated $260K sold.

Allegis Investment Advisors first reported a position in RPRX in Q4 2015 and held it in 9 quarters. The position peaked at $712K in Q3 2016. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.

  • Allegis Investment Advisors reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
  • Allegis Investment Advisors sold 394,206 Repros Therapeutics Inc. shares in Q1 2018, an estimated $260K.
  • Allegis Investment Advisors first reported a position in Repros Therapeutics Inc. in Q4 2015 and held it in 9 quarters.
  • Allegis Investment Advisors's Repros Therapeutics Inc. position peaked at $712K in Q3 2016.
  • 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.

Based on Allegis Investment Advisors's 13F filing for Q1 2018, filed 24 Apr 2018.